UK lags behind in healthcare outcomes index
November 26, 2014Research and Development, Sales and Marketing Japan, NHS, UK, WHO, economist, health outcomes
Whilst healthcare outcomes in the UK arguably remain among the best in the world according to recent findings by The …
Sharp Packaging Services hires MD
November 26, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Mike O’Hara, Sharp Packaging Services
Sharp Packaging Services that is a part of UDG Healthcare has announced that Mike O’Hara has joined the firm as …
Mental and physical health should be treated equally
November 26, 2014Medical Communications, Research and Development, Sales and Marketing Campbell, Lundbeck, depression, kofi annan, wiinberg
The need for a new approach to depression that gives it equal importance to physical health was the focus of …
Cell Medica gets £50 million funding
November 26, 2014Research and Development, Sales and Marketing CMD-003, Cancer, Imperial Innovations, Invesco Perpetual, Woodford Investment Management, celk medica
Cellular immunotherapy development firm Cell Medica has confirmed the completion a £50 million investment round from key backers to progress …
Priority review for Novartis myeloma drug
November 26, 2014Sales and Marketing FDA, Farydak, Novartis, daratumumab, elotuzumab, myeloma, odac
Novartis’ multiple myeloma treatment Farydak has been given an extended review by the FDA after its future seemed in jeopardy …
Institute of Cancer Research names chief executive
November 26, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ICR, Institute of Cancer Research, paul workman
Professor Paul Workman has been appointed as the chief executive of the Institute of Cancer Research. Workman who also becomes …
BioMarin to buy Prosensa in $840 million deal
November 25, 2014Sales and Marketing BioMarin, Prosensa, drisapersen, dystrophy
Rare-disease drug firm BioMarin has finalised its purchase of muscular disease specialist Prosensa in a deal worth over $840 million. …
Lundbeck chief executive resigns amid scandal
November 25, 2014Medical Communications, Sales and Marketing Björklund, Lundbeck, stratified medical, ulf wiinberg
Ulf Wiinberg has resigned from his chief executive post at Denmark-based pharma giant Lundbeck following a beach of its rules …
Virgo Consumer Health promotes to senior team
November 25, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Virgo, natasha weeks, rebecca rhodes
Virgo has promoted its long-standing employee Natasha Weeks (pictured) to the position of director and lead of its Consumer Health …
CHMP nods several drugs through
November 24, 2014Sales and Marketing Boehringer, CHMP, EMA, Esbriet, FDA, Sanofi, nintedanib, ofev
Ten new medicines have been recommended for approval by the EMA’s Committee for Medicinal Products for Human Use (CHMP), among …
Takeda: we’re working on Ebola too
November 24, 2014Research and Development, Sales and Marketing Ebola, GSK, Gates, Obama, WHO, brett wells, pharmafile, rajeev, vaccines, venkaya, venkayya
The president of Takeda Vaccines has told Pharmafile that the Japanese firm has identified compounds that could help prevent infection …
Antibiotics: will the industry saviour please stand up
November 24, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Antibiotics, EAA, MRC, WHO, resistance, susie lunt
The spectre of a new ‘dark ages’ for humanity where common infections begin to kill again is increasingly making itself …
New managing director for Napp Pharmaceuticals
November 24, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Napp, alberto, martinez
Alberto Martinez has joined Napp Pharmaceuticals in the UK as its new managing director, taking over the role from Dietmar …
ABPI: NHS must change to allow stratified drugs
November 21, 2014Research and Development, Sales and Marketing ABPI, NHS, george freeman, personalised, rawal, stratified medicines
The development of stratified medicines – especially in therapy areas outside of oncology – will have a significant effect on …
Future bleak for Novartis’ myeloma drug
November 21, 2014Medical Communications FDA, Farydak, Novartis, ixazomib, myeloma, panobinostat
Novartis suffered a major disappointment with the negative FDA panel vote for multiple myeloma candidate Farydak earlier this month, but …
Ablynx looks to GSK for new chief commercial officer
November 21, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Ablynx, johan heylan
Belgium-based biopharma firm Ablynx has appointed Johan Heylen to be its chief commercial officer and assume responsibility for all commercial …
Global drug spending set to top $1 trillion
November 20, 2014Sales and Marketing Gilead, IMS, Kadcyla, Perjeta, drugs, hepatitis C, sovaldi, spend
Worldwide spending on drugs will reach over $1 trillion in 2014 and $1.3 trillion by 2018, according to a new …
Gilead gets Harvoni boost for Europe
November 20, 2014Sales and Marketing EU, Gilead, HCV, harvoni, hepc, ledipasvir, sofosbuvir, svaldi
Gilead Sciences’ new hepatitis C (HCV) tablet Harvoni has been approved across the European Union to treat the majority of …
Sanofi showcases alirocumab at AHA
November 20, 2014Sales and Marketing Amgen, PCSK9, Regeneron, Sanofi, aha, alirocumab, evolocumab
Sanofi and Regeneron released a battery of new Phase III data on their PCSK9 inhibitor alirocumab this week, reinforcing the …
NICE aims for earlier cancer diagnosis
November 20, 2014Sales and Marketing Cancer, England, NHS, NICE, OECD, UK, baker
NICE is updating its guidance in a bid to help doctors spot the signs and symptoms of cancer as part …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
